A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
2014 ◽
Vol 73
(Suppl 2)
◽
pp. 985.2-985
◽
2015 ◽
Vol 75
(2)
◽
pp. 332-340
◽
2002 ◽
Vol 4
(4)
◽
pp. 345-350
◽
Keyword(s):